32670-02-3

Usage

Structure

Spirocycle containing a cyclobutane ring fused to a 3H-indole ring

Primary Use

Photochemical caging group in biological research

Function

Acts as a light-sensitive protecting group for functional groups in biomolecules (e.g., amino acids, nucleotides)

Activation

Upon exposure to UV light, the spirocyclic structure is cleaved

Outcome

Release of the caged biomolecule, allowing it to exert its biological activity

Applications

Studying neural activity, cell signaling, drug delivery, and other research areas

Upstream product

• 103490-51-3 cyclobutanecarboxylic acid 2-phenylhydrazide 
• 5006-22-4 Cyclobutanecarbonyl chloride 
• 100-63-0 phenylhydrazine 
• 103490-52-4 spiroindol>-2'(1'H)-one 

Relevant academic research and scientific papers

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.